Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Findings from the Study 309–KEYNOTE-775 among patients who had disease progression after the receipt of previous systemic platinum-based therapy
IMbassador 250 findings indicate that biology associated with response to immune checkpoint inhibition is present in few patients with metastatic castration-resistant prostate cancer
PANDA challenge consortium cohort report
Genetic subtyping more accurately reflects clinical behaviour than reliance on pathologic classification only
Findings from the COMBI-I study
Final overall survival analysis from the HER2CLIMB study
Findings from the FinXX study
Findings from the International Replication Repair Deficiency Consortium registry-based study
Findings from the GOG-0261 study
Efficacy and safety data in a larger number of patients and longer follow-up from KEYNOTE-158 study
Patients with cancer who develop breakthrough COVID-19 remain at risk of severe outcomes despite full vaccination
Findings from a meta-analysis of two randomised controlled phase III studies of the STAMPEDE platform protocol
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
